{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:30:26Z","timestamp":1790220626481,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005897","name":"Societe francaise de dermatologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jclinepi.2024.111406","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T07:29:52Z","timestamp":1717140592000},"page":"111406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1905-0780","authenticated-orcid":false,"given":"Quentin","family":"Beytout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-223X","authenticated-orcid":false,"given":"Sivem","family":"Afach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Guelimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-6839","authenticated-orcid":false,"given":"Laurence","family":"Le Cleach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2024.111406_bib1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111406_bib2","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2024.111406_bib3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2024.111406_bib4","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report: safety of TNF-Inhibitor Therapy","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jclinepi.2024.111406_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jclinepi.2024.111406_bib6","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12876-021-01936-w","article-title":"Severe drug-associated colitis with Crohn\u2019s features in setting of ixekizumab therapy for chronic plaque psoriasis","volume":"21","author":"Mu","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2017.07.047","article-title":"Serious infections among a large cohort of subjects with systemically treated psoriasis","volume":"77","author":"Dobry","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjd.19244","article-title":"Meta-analysis results do not reflect the real safety of biologics in psoriasis","volume":"184","author":"Afach","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib11","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinternmed.2009.313","article-title":"Adverse events in randomized trials: neglected, restricted, distorted, and silenced","volume":"169","author":"Ioannidis","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib12","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.pain.2012.08.009","article-title":"Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review","volume":"153","author":"Smith","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.jclinepi.2024.111406_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jclinepi.2021.04.020","article-title":"Time to improve the reporting of harms in randomized controlled trials","volume":"136","author":"Junqueira","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib14","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of safety results in published reports of randomized controlled trials","volume":"169","author":"Pitrou","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials: the CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2024.111406_bib16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cct.2008.11.004","article-title":"The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry","volume":"30","author":"Han","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jclinepi.2024.111406_bib19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJMsr0806582","article-title":"Progress and deficiencies in the registration of clinical trials","volume":"360","author":"Wood","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001566","article-title":"Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals","volume":"10","author":"Riveros","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/M13-0480","article-title":"Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications","volume":"160","author":"Hartung","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12916-015-0430-4","article-title":"Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles","volume":"13","author":"Tang","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib23","first-page":"1289","article-title":"Defining treatment-emergent adverse events with the medical dictionary for regulatory Activities (MedDRA)","volume":"35","author":"Nilsson","year":"2001","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.jclinepi.2024.111406_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2013.52.2219","article-title":"Adverse event reporting in cancer clinical trial publications","volume":"32","author":"Sivendran","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jclinepi.2024.111406_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib27","doi-asserted-by":"crossref","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2024.111406_bib28","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jclinepi.2024.111406_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/ebmed-2017-110715","article-title":"Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic review","volume":"22","author":"Hadi","year":"2017","journal-title":"Evid Based Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijid.2020.09.1470","article-title":"Use of hydroxychloroquine and chloroquine in COVID-19: how good is the quality of randomized controlled trials?","volume":"101","author":"Mazhar","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jclinepi.2024.111406_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00228-020-03008-6","article-title":"Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19","volume":"77","author":"Kow","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jama.285.4.437","article-title":"Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas","volume":"285","author":"Ioannidis","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2024.111406_bib33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/M18-0343","article-title":"Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review","volume":"169","author":"Bafeta","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003436","article-title":"Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension","volume":"3","author":"Hodkinson","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jclinepi.2024.111406_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eplepsyres.2015.04.019","article-title":"Assessment of the quality of harms reporting in non-randomised studies and randomised controlled studies of topiramate for the treatment of epilepsy using CONSORT criteria","volume":"114","author":"Carmichael","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jclinepi.2024.111406_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041174","article-title":"Challenges in coding adverse events in clinical trials: a systematic review. Choonara I","volume":"7","author":"Schroll","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jclinepi.2024.111406_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021753","article-title":"Role of supplementary material in biomedical journal articles: surveys of authors, reviewers and readers","volume":"8","author":"Price","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jclinepi.2024.111406_bib40","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2024.111406_bib41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2024.111406_bib43","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib44","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib45","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti\u2013Interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab\u2019 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/09546634.2012.658015","article-title":"The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)","volume":"24","author":"Strohal","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jclinepi.2024.111406_bib48","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","volume":"167","author":"Gottlieb","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111406_bib50","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib52","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bjd.12060","article-title":"A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis","volume":"168","author":"Ortonne","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib53","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib56","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib57","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111406_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib60","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib61","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib62","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/exd.12710","article-title":"Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis","volume":"24","author":"Reich","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib63","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib64","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib65","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study","volume":"31","author":"Cai","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib66","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib67","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib68","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib69","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","article-title":"Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial","volume":"78","author":"Elewski","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12895-016-0048-z","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib72","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111406_bib73","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/1346-8138.13829","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial","volume":"44","author":"Ohtsuki","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib74","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib75","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bjd.15707","article-title":"Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib76","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jclinepi.2024.111406_bib77","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib78","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111406_bib79","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.14504","article-title":"An anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib80","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","article-title":"Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results)","volume":"8","author":"Bagel","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jclinepi.2024.111406_bib81","first-page":"33","article-title":"Early onset of clinical improvement with ixekizumab in a randomized, open-label study of patients with moderate-to-severe plaque psoriasis","volume":"11","author":"Khattri","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib82","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bjd.16426","article-title":"Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib83","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib84","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib85","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111406_bib86","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","article-title":"Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study","volume":"31","author":"Ferris","year":"2020","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jclinepi.2024.111406_bib87","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjd.18384","article-title":"A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib88","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1346-8138.14941","article-title":"Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the Sust IMM phase 2\/3 trial","volume":"46","author":"Ohtsuki","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib89","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111406_bib90","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjd.18696","article-title":"Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS)","volume":"183","author":"Tha\u00e7i","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib91","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib92","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"Von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib93","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib94","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo controlled trial of secukinumab on aortic vascular inflammation in moderate to severe plaque psoriasis (VIP-S)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib95","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chin Med J"},{"key":"10.1016\/j.jclinepi.2024.111406_bib96","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/jdv.16932","article-title":"A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)","volume":"35","author":"Pinter","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib97","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Van Voorhees","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib98","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib99","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdermsci.2023.01.003","article-title":"Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study","volume":"109","author":"Blauvelt","year":"2023","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jclinepi.2024.111406_bib100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib101","article-title":"Efficacy and safety of ixekizumab versus adalimumab in biologic-na\u00efve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial","volume":"12","author":"Reich","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.jclinepi.2024.111406_bib102","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1080\/09546634.2021.1902925","volume":"33","author":"Sigurgeirsson","year":"2022","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jclinepi.2024.111406_bib103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjd.20481","article-title":"Direct comparison of risankizumab and fumaric acid esters in systemic therapy-na\u00efve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial","volume":"186","author":"Tha\u00e7i","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib104","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111406_bib105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo-controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2024.111406_bib106","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib107","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2024.111406_bib108","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1080\/09546634.2021.1914812","article-title":"Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis","volume":"33","author":"Blauvelt","year":"2022","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jclinepi.2024.111406_bib109","first-page":"53","article-title":"Fumarate (PPC-06) extended release tablets in patients with moderate-to-severe plaque psoriasis: safety and efficacy results from the randomized, double-blind, placebo-controlled AFFIRM study","volume":"15","author":"Mrowietz","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib110","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjd.20971","article-title":"Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial","volume":"186","author":"Augustin","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib111","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jclinepi.2024.111406_bib112","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435624001616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435624001616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T18:43:53Z","timestamp":1729190633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435624001616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":110,"alternative-id":["S0895435624001616"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111406","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111406"}}